Items Tagged ‘cd19’

January 19, 2016

Blincyto® is Promising New Treatment Option for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia


Amgen, a biotechnology company, has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings from a Phase 2 trial in a recent press release. Acute lymphoblastic leukemia is a fast-growing cancer of the white blood cells. Relapsed/refractory ALL in […]

View full entry

Tags: Acute Lymphoblastic Leukemia, acute lymphoblastic lymphoma, all, blincyto, cd19, immunotherapy, Leukemia, News, Philadelphia chromosome positive

July 21, 2014

Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment


A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment, which involves extracting specific white blood cells from a patient and modifying them before infusion back into the patient, is currently involved in a phase […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, cd19, Chronic Lymphocytic Leukemia, CLL, Indolent/Low Grade Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, News, Non-Hodgkin's Lymphoma